Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Roche’s new multiple sclerosis drug set for early FDA approval
July 7, 2016
Crohn’s disease can originate from specialized intestinal cells, more than two hundred genes identified
July 7, 2016
Show all

Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

A global survey of people with psoriasis reveals discrimination of many of those with this condition.

Novartis today released new results from the largest global survey to date of people with psoriasis. Findings reveal 84% of people with moderate-to-severe psoriasis suffer discrimination and humiliation, with many being stared at in public (40%) as a result of their medical condition. In addition, the results from more than 8,300 participants show that people with psoriasis have very low treatment expectations of achieving clear skin.

“Novartis thanks all the participants who took part in this important survey. The only way we can improve patients’ lives is to listen to them and work with the community to challenge the status quo,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. “This survey marks our commitment to support the World Health Organization’s (WHO) resolution to make psoriasis a global health priority, fighting the stigma and ignorance associated with psoriasis and advancing patient care.”

Over 8,300 people from 31 countries took part in the survey, and it is also the first of its kind to explore perceptions of clear skin in psoriasis. This is the largest ever partnership between Novartis and patient organizations, including 25 groups from around the world.

Read Full Article: Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

Read Full Article: Global survey reveals 84% of psoriasis patients suffer discrimination, humiliation

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.